CONFLICT OF INTEREST STATEMENT
MR, Nordisk, NNF
HEART
JL has a consultancy agreement with Medtronic and has received speakers fee from Bayer and Novartis, and a research grant ZonMW LEAP trial project number 852002101. MR has received consultancy fees from Medtronic, Arca Biopharma Inc, and Roche to the institution; MR has received unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001; from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED‐CVD (CVON2017‐11); from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON‐AI (2018B017)); from the European Union's Horizon 2020 research and innovation program under grant agreement: EHRA‐PATHS (945260). IVG has received consultancy fees Institute from Medtronic, Daiichi, BMS, Bayer and Roche to the institution. IVG has received unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; from the European Union's Horizon 2020 research and innovation program under grant agreement: EHRA‐PATHS (945260). DL has received consultancy fees from Medtronic, Biotronik, Bayer and Itamar to the University of Maastricht. DL has received unrestricted research grant from the European Union's Horizon 2020 research and innovation program under grant agreement: EHRA‐PATHS (945260); from the Novo Nordisk Foundation; NNF Young Investigator Awards 2021 under grant agreement NNF21OC0066480. The other authors declare no conflicts of interest.